Bone News and Research

RSS

Study finds bone marrow stem cell therapy improves efficacy in chronic heart failure

Bone marrow stem cell therapy improves ventricular performance, quality of life and survival in patients with chronic heart failure, according to results from the STAR-heart study.

30 Aug 2010

New high throughput sequencing technology to identify genetic defects in rare diseases

The majority of rare diseases are hereditary. But despite significant progress in genome research, in most cases their exact cause remains unclear. The discovery of the underlying genetic defect is, however, a prerequisite for their definitive diagnosis and the development of innovative approaches to their treatment. Scientists at the Max Planck Institute for Molecular Genetics and the Institute of Medical Genetics at the Charit- Universit-tsmedizin - Berlin have succeeded in using a new process with which all of the genes in the human genome can be analysed simultaneously.

30 Aug 2010

Asia-Pacific convention on osteoporosis management

Clinicians, researchers and allied health professionals with an interest in osteoporosis and its prevention, diagnosis and management, are invited to convene in Singapore for the IOF Regionals - 1st Asia-Pacific Osteoporosis Meeting from December 10-13, 2010.

30 Aug 2010

Exactech announces acquisition of minimally invasive spine product portfolio from VertiFlex

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the acquisition of several innovative spine product lines and all related technology from VertiFlex, Inc. a leading developer of minimally invasive and motion preserving spinal surgery technologies.

27 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.

27 Aug 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

ThermoGenesis files Certificate of Amendment for reverse stock split

ThermoGenesis Corp.,a leading supplier of innovative products and services that process and store adult stem cells, said it has filed a Certificate of Amendment to its Amended and Restated Certification of Incorporation to effect its previously announced one-for-four reverse stock split of its common stock.

27 Aug 2010

NICE suggests bortezomib, thalidomide for multiple myeloma patients

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance which recommends the drugs bortezomib and thalidomide as first-line therapies for some patients with multiple myeloma, a type of cancer that affects cells in the bone marrow.

27 Aug 2010

DePuy Orthopaedics announces voluntary recall of ASR XL Acetabular and Hip Resurfacing systems

DePuy Orthopaedics, Inc., announced it is voluntarily recalling the ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System used in hip replacement surgery due to the number of patients who required a second hip replacement procedure, called a revision surgery.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

26 Aug 2010

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Georgia medical technology company, recently received the rights to a new patent to bolster its SoftWave technology portfolio. The patent covers a method of reattaching damaged soft tissue to bone.

26 Aug 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

NeoStem responds to court ruling blocking government funding for embryonic stem cell research

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, commented today on the ruling this week of a U.S. District Court blocking the federal government from funding research involving human embryonic stem cells. In issuing a preliminary injunction, the judge said it violated a law first passed in 1996 prohibiting federal money for research where a human embryo is destroyed.

25 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

Sea food for babies

Has your toddler eaten fish today? A University of Illinois food science professor has two important reasons for including seafood in your young child's diet, reasons that have motivated her work in helping to develop a tasty, nutritious salmon baby food for toddlers.

25 Aug 2010

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

25 Aug 2010

Bone News and Research

Study finds bone marrow stem cell therapy improves efficacy in chronic heart failure

New high throughput sequencing technology to identify genetic defects in rare diseases

Asia-Pacific convention on osteoporosis management

Exactech announces acquisition of minimally invasive spine product portfolio from VertiFlex

FDA approves Novartis' Tekamlo for treatment of high blood pressure

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Researchers recommend traumatic brain injury reclassification for additional funding

ThermoGenesis files Certificate of Amendment for reverse stock split

NICE suggests bortezomib, thalidomide for multiple myeloma patients

DePuy Orthopaedics announces voluntary recall of ASR XL Acetabular and Hip Resurfacing systems

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

NeoStem responds to court ruling blocking government funding for embryonic stem cell research

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

Sea food for babies

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News